Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BBOX1 | O75936 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5009177 | 0.98 | BBOX1 (0.47) | BBOX1SMN1; SMN2LMNATSHRAPOBEC3A | |
| SCHEMBL24072018 | 0.94 | BBOX1 (0.44) | BBOX1SMN1; SMN2LMNATSHRAPOBEC3A | |
| SCHEMBL5011415 | 0.92 | BBOX1 (0.46) | BBOX1SMN1; SMN2LMNATSHRAPOBEC3A | |
| Lithium Ion SCHEMBL5010373 | 0.89 | BBOX1 (0.41) | BBOX1SMN1; SMN2LMNATSHRAPOBEC3A | |
| SCHEMBL24072021 | 0.88 | KDM4E (0.42) | BBOX1SMN1; SMN2LMNATSHRAPOBEC3A | |
| Trifluoromethanesulfonic Acid SCHEMBL5012756 | 0.86 | BBOX1 (0.39) | BBOX1SMN1; SMN2LMNATSHRAPOBEC3A | |
| Trifluoromethanesulfonic Acid SCHEMBL5010382 | 0.81 | LMNA (0.38) | BBOX1SMN1; SMN2LMNATSHRAPOBEC3A | |
| SCHEMBL8108400 | 0.81 | HPGD (0.41) | BBOX1SMN1; SMN2LMNATSHRAPOBEC3A | |
| SCHEMBL3190470 | 0.80 | BBOX1 (0.50) | BBOX1LMNATSHRAPOBEC3AAPOBEC3G | |
| Sulfuric Acid SCHEMBL21195044 | 0.78 | BBOX1 (0.44) | BBOX1LMNATSHRAPOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569595-B2 | Bioprosthetic tissue preparation | EDWARDS LIFESCIENCES CORPORATION (US) | 2026-03-10 | — | — | US | claimed |
| WO-2024136320-A1 | COMPOSITION FOR SINGLE-CELL PROTEOMICS ANALYSIS, SAMPLE TREATMENT METHOD USING SAME, AND METHOD FOR UNIFYING LABELING OF ULTRA-SMALL AMOUNTS OF PEPTIDES | 재단법인대구경북과학기술원 | 2024-06-27 | — | — | WO | claimed |
| CN-118166551-A | Fabric with oil-in-water emulsion demulsification function and preparation method thereof | 嘉兴学院 | 2024-06-11 | — | — | CN | claimed |
| US-20240000999-A1 | SOLUBILIZATION OF ANTIGEN COMPONENTS FOR REMOVAL FROM TISSUES | UNIV CALIFORNIA (US) | 2024-01-04 | — | — | US | claimed |
| US-20230101362-A1 | RNA STABILIZATION | TEAM MEDICAL LLC | 2023-03-30 | — | — | US | claimed |
| WO-2023044455-A2 | RNA STABILIZATION | TEAM MEDICAL LLC (US) | 2023-03-23 | — | — | WO | claimed |
| CN-114258310-A | Bioprosthetic tissue preparation | 爱德华兹生命科学公司 | 2022-03-29 | — | — | CN | claimed |
| EP-3965841-A1 | BIOPROSTHETIC TISSUE PREPARATION | Edwards Lifesciences Corporation (US) | 2022-03-16 | — | — | EP | claimed |
| WO-2019078655-A1 | COMPOSITION FOR INFILTRATING BIOMOLECULE INTO TISSUE INCLUDING SULFOBETAINE-BASED ZWITTERIONIC SURFACTANT, AND USE THEREOF | 재단법인대구경북과학기술원 | 2019-04-25 | — | — | WO | claimed |
| US-7906109-B2 | Pharmaceutical composition comprising an active principal and sulphobetaine | LEK PHARMACEUTICALS D.D. (SL) | 2011-03-15 | — | — | US | claimed |
| EP-1729794-B1 | A PHARMACEUTICAL COMPOSITION COMPRISING A NON-DETERGENT SULPHOBETAINE | LEK PHARMACEUTICALS (SI) | 2008-07-09 | — | — | EP | claimed |
| US-20070184019-A1 | Pharmaceutical composition comprising an active principal and sulphobetaine | LEK PHARMACEUTICALS D.D. (SI) | 2007-08-09 | — | — | US | claimed |
| EP-1729794-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE PRINCIPLE AND SULPHOBETAINE | LEK Pharmaceuticals D.D. (SI) | 2006-12-13 | — | — | EP | claimed |
| WO-2005060989-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE PRINCIPLE AND SULPHOBETAINE | LEK PHARMACEUTICALS D.D. (CH) | 2005-07-07 | — | — | WO | claimed |
| EP-4725960-A2 | SWEET PROTEIN FROM TRUFFLE | Mycotechnology, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4361621-B1 | SAMPLE ANALYSIS METHOD, CAPILLARY ELECTROPHORESIS SOLUTION, AND SAMPLE ANALYSIS KIT | ARKRAY INC (JP) | 2026-04-08 | — | — | EP | disclosed |
| US-20260092310-A1 | CAS12A COMPOSITIONS AND METHODS | NEW ENGLAND BIOLABS, INC. (US) | 2026-04-02 | — | — | US | disclosed |
| US-20070184019-A1 | Pharmaceutical composition comprising an active principal and sulphobetaine | LEK PHARMACEUTICALS D.D. (SI) | 2007-08-09 | — | — | US | disclosed |
| EP-1729794-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE PRINCIPLE AND SULPHOBETAINE | LEK Pharmaceuticals D.D. (SI) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005060989-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE PRINCIPLE AND SULPHOBETAINE | LEK PHARMACEUTICALS D.D. (CH) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092310-A1 | CAS12A COMPOSITIONS AND METHODS | RNASEL, RBM12, NT5C2 | BBOX1 1958/4885SMN1; SMN2 188/4885LMNA 42/4885 |
| US-12569595-B2 | Bioprosthetic tissue preparation | BCHE, LNPEP, DPEP1 | BBOX1 716/4885SMN1; SMN2 4272/4885LMNA 3619/4885 |
| US-20070184019-A1 | Pharmaceutical composition comprising an active principal and sulphobetaine | SCN2B, SCN1B, SPTSSB | BBOX1 1678/4885SMN1; SMN2 943/4885LMNA 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.